Amylin Speculation Intensifies, Part 2: Activist Shareholders Grow Restless
This article was originally published in The Pink Sheet Daily
Executive Summary
Eastbourne Capital says it wants Amylin to find a buyer. Is Lilly ready for another billion dollar deal?
You may also be interested in...
Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?
Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class
Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?
Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class
Next Chapter In The Amylin Chronicles: Job Cuts, Restructuring
Troubled by slower Byetta growth and uncertainty around the development of a long-acting version, Amylin will cut 25 percent of its San Diego workforce.